Cannabis Science Negotiates Commercialization Deal to Bring Cannabis Science Brand Formulations Immediately into the Californ...
December 14 2011 - 3:04PM
Business Wire
Cannabis Science, Inc. (OTCBB:CBIS.ob), a pioneering US biotech
company developing pharmaceutical cannabis products, is pleased to
announce it has entered final negotiations to bring Cannabis
Science Brand of Pharmaceutical products into California.
Following the release of our cannabis extract based formulation
in Colorado, and international anecdotal cases reports from
patients with Cancer, Cannabis Science is finalizing agreements to
expand our business into California.
This new strategic partnership would allow Cannabis Science to
better satisfy the demand for its formulations by making them
available to more than 1.4 million cancer patients in California.
This strategic alliance also brings to the table significant
resources for Cannabis Science in California including laboratories
for quality assurance and testing, an educational platform to
distribute information about the science of cannabis (everything on
should know from the seed to sale) Additionally, as part of the
deal we will acquire organically produced strains for our
scientific medicinal formulations. Furthermore, if California goes
fully legal in 2014, it should bring down production costs
and savings could be passed along to the patients.
Dr. Melamede stated “ For too long patients have requested our
formulations, as a result we have gathered anecdotal reports thru
personal testimonials that have demonstrated to us the need for our
products in California. We look forward to bringing these
products thru the California regulatory system in the near
future. Similarly, as the laws allow, we intend to bring our
products to other medical marijuana states through additional
strategic mergers, acquisitions, and partnerships.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical
grade medical marijuana research and development. The Company works
with world authorities on phytocannabinoid science targeting
critical illnesses, and adheres to scientific methodologies to
develop, produce and commercialize phytocannabinoid-based
pharmaceutical products. In sum, we are dedicated to the creation
of cannabis-based medicines, both with and without psychoactive
properties, to treat disease and the symptoms of disease, as well
as for general health maintenance.
Forward Looking Statements; This Press Release includes
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Act of
1934. A statement containing works such as "anticipate," "seek,"
intend," "believe," "plan," "estimate," "expect," "project,"
"plan," or similar phrases may be deemed "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Some or all of the events or results
anticipated by these forward-looking statements may not occur.
Factors that could cause or contribute to such differences include
the future U.S. and global economies, the impact of competition,
and the Company's reliance on existing regulations regarding the
use and development of cannabis-based drugs. Cannabis Science, Inc.
does not undertake any duty nor does it intend to update the
results of these forward-looking statements.